Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

Norm has also worked on several recent M&A deals in the biotech industry. “We are excited to welcome Norm to the Organovo team,” said Keith Murphy, Executive Chairman. “With his extensive experience, ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Shares of NASDAQ ONVO opened at $0.37 on Friday. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0. ...

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.